A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

Clinical trial NCT07619131 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07619131
Sponsor: AstraZeneca
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hypercholesterolaemia

Start date: 2026-08-17
Primary completion: 2027-07-30
Enrollment: 600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.